Eplivanserin

Sanofi Aventis kwupụtara na Disemba 2009 na ọ na-ewepụ akwụkwọ ya maka nkwado nke eplivanserin site na Nchịkwa nri na ọgwụ US na Agencylọ Ọrụ Ọgwụ na Europe.^[1]

Usoro nke ọrụ

Eplivanserin bụ onye na-emegide serotonin receptor subtype 5-HT2A. N'adịghị ka ọgwụ ndị na-eme ka mmadụ kwụsị ịrụ ọrụ nkụzi kasị dị umeala na 5-HT2A receptors (dịka, mirtazapine, clozapine, risperidone), eplivanserin enweghị njikọ ọ bụla na dopamine, histamine na adrenergic receptors.^[2]

Nsonaazụ ọmụmụ

N'ime nnwale ọgwụgwọ nke Phase II nke placebo na-achịkwa na mmadụ 351, eplivanserin belatara oge ụra site na afo nwela onwa iri nkeji 39 (ma e jiri ya tụnyere nkeji 26 n'okpuru placebo).^[2]

Nchịkọta

Patent: Chinese

Njikọ dị n'etiti 2'-Fluoroacetophenone [445-27-2] (5) & 4-hydroxybenzaldehyde [123-08-0] (6) na-enye chalcone dị n'agbata (nakwa enone), ya bụ. CID:53982926 (7).

(2-chloroethyl) dimethylamine (CDMA) na acetone oxime na-emeghachi omume ọnụ iji nye dimethyhaminoacetoxime (DMA acetoxime), CID:16641114 (3).

Hụkwa

Pimavanserin
Volinanserin

Ntụaka

↑ "Sanofi-Aventis Discontinues Eplivanserin For Insomnia", Dow Jones & Co, 21 December 2009. Retrieved on 27 January 2010.
↑ ^2.0 ^2.1 (2008) "5-HT(2A) inverse-agonists for the treatment of insomnia". Current Topics in Medicinal Chemistry 8 (11): 969–76. DOI:10.2174/156802608784936700. PMID 18673166.

[1] "Sanofi-Aventis Discontinues Eplivanserin For Insomnia", Dow Jones & Co, 21 December 2009. Retrieved on 27 January 2010.

[Teergarden-2] 2.0 ^2.1 (2008) "5-HT(2A) inverse-agonists for the treatment of insomnia". Current Topics in Medicinal Chemistry 8 (11): 969–76. DOI:10.2174/156802608784936700. PMID 18673166.

[1]

[2]